Phones in class, a 25-year prescription gone wrong, pickleball's hidden danger, and why your spin class is too loud — four findings hiding in everyday care.
Pain reprocessing therapy produced small but measurable reductions in cross-modal sensory amplification, pointing to a broader neurological signature of chronic back pain than previously recognized.
Navepegritide is described as the first therapy to deliver continuous C-type natriuretic peptide exposure over a weekly dosing interval in eligible pediatric patients.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Multicenter outcomes study finds cisplatin dose drives toxicity differences between guideline-endorsed regimens, with kidney function decline predicting cardiovascular risk